PharmAthene has appointed Linda Chang as senior vice president (SVP) and chief financial officer (CFO). Chang is responsible for accounting, finance, IT and investor relations functions.
Prior to joining PharmAthene, Chang spent 11 years at Human Genome Sciences, most recently as senior director of finance. She was a key member of the team that raised over US$1.8bn in equity, issued and restructured over US$600m in convertible debt, and transacted over US$950m in real estate financing. Chang also managed as much as US$1.6 bn in investment portfolios, negotiated letters of credit (L/Cs), and participated in business development efforts, including the purchase of Principia Corporation.
Prior to Human Genome Sciences, Chang was an associate at Booz Allen & Hamilton from 1997 to 2000. Earlier in her career, Chang worked at Grant Thornton and Otsuka America Pharmaceuticals.
Chang is a certified public accountant (CPA). She earned an MBA as well as a Master of Accountancy degree from the University of Georgia and a BS from the University of California, Riverside.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.